Physician profile
Roxana A Donea
NPI 1205898400
$808.66
in general payments reported to CMS, 2019-2025
13 companies · $71.13 in 2025
The $71.13 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $29.68 · 2021: $158 · 2022: $123 · 2023: $89.22 · 2024: $123 · 2025: $71.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $207.60 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $152.00 | 2019-2024 | |
| Pfizer INC. | $80.30 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $74.43 | 2020-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $73.26 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $58.28 | 2019-2024 | Recarbrio, Zerbaxa, Dificid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.44 | 2019-2024 | Lifevest |
| Chiesi USA, INC. | $30.26 | 2025 | Cleviprex |
| Viatris Specialty LLC | $22.95 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.56 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.21 | 2021 | |
| Allergan, INC. | $13.94 | 2019 | |
| Glaxosmithkline, LLC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxana Donea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.